Cannabidiol (CBD)
-
How did the U.S. arrive at 0.3% by dry weight?:
- The 0.3% THC mandate is a problematic interpretation and application of early cannabis science. In 1976, Canadian horticulturalists Ernest Small and Arthur Cronquist published an article in Taxon, entitled “A Practical and Natural Taxonomy in Cannabis,” in which they provide the seminal demarcation between “industrial hemp” vs “marijuana”2 that has been adopted by governments around the world. In their words: It will be noted that we arbitrarily adopt a concentration of 0.3% Delta9-THC (dry weight basis) in young, vigorous leaves of relatively mature plants as a guide to discriminating two classes of plants. This is based on standard-grown material in Ottawa in gardens, greenhouses and growth chambers, and of course on our analytical techniques. Dr. C. E. Turner, who has conducted extensive chemical analysis of Cannabis at the University of Mississippi, has agreed (pers. com.) that this is a reasonable figure to discriminate two classes of plants. The major scientific problem (besides “we arbitrarily adopt…”) is that the widely implemented 0.3% THC concentration limit is often applied to flowering tops (where cannabinoid production is concentrated) instead of the “young, vigorous leaves of relatively mature plants” identified by Small and Cronquist. https://legislature.vermont.gov/Documents/2018/WorkGroups/House%20Agriculture/Hemp/W~Cary%20Giguere~THC%20Content~3-29-2018.pdf
-
Know properties with synergistic terpenes
- Anti-inflammatory (Hampson et al., 1998)
- Limonene et al
- Anti-convulsant (Jones et al., 2010)
- Linalool
- Anti-oxidant (Hampson et al., 1998)
- Limonene et al.
- Anti-psychotic
- Anti-anxiety via 5-HT1A (Russo et al., 2005)
- Linalool
- Limonene
- Cytotoxic versus breast cancer (Ligresti et al., 2006)
- Limonene
- Effective versus MRSA (Appendino et al., 2008)
- Pinene
- ↑ adenosine A2A signalling (Carrier et al., 2006)
- Linalool
- Treatment of addiction
- Caryophyllene
- Decreases sebum/sebocytes (Biro et al., 2009)
- Pinene
- limonene
- linalool
- Anti-inflammatory (Hampson et al., 1998)
Studies:
- 2024
- Cannabis-containing cream for CKD-pruritus: A double-blind, placebo-controlled trial. https://www.kidneymedicinejournal.org/article/S2590-0595(24)00105-5/fulltext
- Cannabidiol (CBD) and Hemp oil use in veterans using a VA pain clinic: A cross-sectional survey study. https://www.tandfonline.com/doi/full/10.1080/10550887.2024.2355365?
- Cannabidiol (CBD) products: Use patterns and perceptions within a sample of anxious users. https://www.tandfonline.com/doi/full/10.1080/10826084.2024.2369153
- Single and Combined effects of Cannabigerol (CBG) and Cannabidiol (CBD) in Mouse Models of Oxaliplatin-Associated Mechanical Sensitivity, Opioid Anti-nociception, and Naloxone-precipitated Opioid withdrawal. https://pubmed.ncbi.nlm.nih.gov/38927352/
- Lab Testing reveals the Reality behind Amazon's Hemp Market. https://cbdoracle.com/news/amazon-hemp-market-study/
- Cannabidiol bioavailability is non-monotonic with a long terminal elimination half-life: A pharmacokinetic modeling-based analysis. https://pubmed.ncbi.nlm.nih.gov/38624257/
- Cannabidiol and its potential evidence-based psychiatric benefits- A critical review. https://pubmed.ncbi.nlm.nih.gov/38267003/
- Cannabidiol usage, efficacy and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study. https://pubmed.ncbi.nlm.nih.gov/38487574/
- Cannabidiol intervention for muscular tension, pain and sleep bruxism intensity- a randomized double-blind clinical trial. https://www.mdpi.com/2077-0383/13/5/1417
- Examination of the effects of cannabidiol on menstrual-related symptoms. https://psycnet.apa.org/fulltext/2024-61679-001.html
- 2023
- The therapeutic potential of cannabidiol in revolutionizing Opioid Use Disorder management. https://assets.cureus.com/uploads/review_article/pdf/214898/20231216-18759-sq66bh.pdf
- Feasibility of a cannabidiol (CBD) dominant cannabis based medicinal product for the treatment of long covid symptoms: A single arm open-label feasibility trial. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15988
- A randomized, double-blind, placebo controlled, repeated-dose pilot study of the safety, tolerability and preliminary effects of a cannabidiol (CBD) and cannabigerol (CBG) based beverage powder to support recovery from delayed onset muscle soreness (DOMS). https://pubmed.ncbi.nlm.nih.gov/37947792/
- Long-term Self dosing CBD users, Indications, Dosage, and Self-Perceptions on General Health/Symptoms and Drug use. https://pubmed.ncbi.nlm.nih.gov/37900894/
- Cannabidiol as an adjunctive treatment for acute bipolar depression: A pilot study. https://pubmed.ncbi.nlm.nih.gov/37920963/
- Antihypertensive effects of CBD are mediated by altered inflammatory response: a sub-study of the Hyper-H21-4 trial. https://www.sciencedirect.com/science/article/pii/S1756464623004735?
- Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy. https://www.annalsofoncology.org/article/S0923-7534(23)01692-7/fulltext
- Highly purified cannabidiol efficacy and safety in a cohort of adult patient with various types of drug-resistant epilepsies. https://pubmed.ncbi.nlm.nih.gov/37806886/
- Consumer perception, knowledge, and uses of Cannabidiol (CBD). https://meridian.allenpress.com/mhc/article/13/5/217/496172?
- CBD as a cure-all? The impacts of state-level legalization of prescription cannabidiol on opioid prescriptions. https://onlinelibrary.wiley.com/doi/10.1002/soej.12667
- Real life experience with purified cannabidiol treatment for refractory epilepsy: A multi-center retrospective study. https://www.pedneur.com/article/S0887-8994(23)00362-4/fulltext
- Eight weeks of daily cannabidiol supplementation improves sleep quality and immune cell cytotoxicity. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574483/
- Effects of cannabidiol on metabolic modulation and improving sports performance: A systematic review. https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/view/330
- Perceptions and opinions of Cannabidiol in the orthopedic and sports medicine community. https://journals.sagepub.com/doi/full/10.1177/23259671231191766
- Effects of CBD on the physiology of Nile tilapia, (oreochromisn niloticus) as a chronic stress mitigating agent in vivo. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0290835
- CBD safety profile: Real-world evidence study shows compelling results for full spectrum CBD. https://www.endocannabinoidmedicine.com/news/cbd-safety-profile-real-world-evidence-study-shows-compelling-results-for-full-spectrum-cbd/
- The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized, placebo controlled trial. https://pubmed.ncbi.nlm.nih.gov/37552290/
- The effects of long-term self-dosing of cannabidiol on drowsiness, testosterone levels and liver function. https://pubmed.ncbi.nlm.nih.gov/36968131/
- Cannabidiol acts as a molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators. https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(23)00249-0
- Cannabidiol's impact on drug metabolization. https://pubmed.ncbi.nlm.nih.gov/37541924/
- Daily Cannabidiol Administration for 10 weeks modulates hippocampal and amygdalar resting-state functional connectivity in Cannabis users: A Functional Magnetic Resonance Imaging Open Label Clinical trial. https://www.liebertpub.com/doi/10.1089/can.2022.0336
- A Systemic review of Cannabidiol trials in Neurodevelopmental disorders. https://pubmed.ncbi.nlm.nih.gov/37543051/
- Update on Cannabidiol Clinical toxicity and Adverse Effects: A systematic Review. https://www.eurekaselect.com/article/130324
- Cannabidiol and Cannabigerol exert antimicrobial activity without compromising skin microbiota. https://www.mdpi.com/1422-0067/24/3/2389
- (2022)
- The Safety and Effectiveness of Commercially available Cannabidiol Products for Health and Well-being: A randomized, Multi-arm Open-label waitlist-controlled trial. (Saleska, et al, 2022) https://www.liebertpub.com/doi/full/10.1089/imr.2022.0081
- Dr. Sulak and Healer.com's guide to CBD/CBDa: https://healercbd.com/wp-content/uploads/2021/05/Healer-CBD-CBDA-eBook.pdf?utm_source=Klaviyo&utm_medium=flow&_kx=fVI32Zji5D8YALVRl8Kk8eO_XaFEb7CrKqw0kSWrhcU%3D.Tb8HXH
- The complete guide to CBD (cannabidiol): https://www.leafly.com/news/cbd/what-is-cbd?utm_source=SailThru&utm_medium=email_news&utm_campaign=Newsletters_11272019_Wed
- FDA Says CBD Products Run ‘Real Risks’. Rather than regulate, FDA issues misinformation: https://cannabisnow.com/fda-says-cbd-products-run-real-risks/?utm_campaign=Daily%20Morning%20News&utm_source=hs_email&utm_medium=email&utm_content=80147502&_hsenc=p2ANqtz-81tCS3wQBF3QB_siRiNgXZYkyIfhHxPPjXFwKzZMdeME7vIQXoUcCte1cF6915mAKR-9AIYlew3bTa1rB7EMHKxWQixw&_hsmi=80147709
- The FDA is worried about CBD. Should you be concerned? https://www.leafly.com/news/cbd/the-fda-is-worried-about-cbd-should-you-be-concerned?utm_source=SailThru&utm_medium=email_news&utm_campaign=Newsletters_12042019_Wed&utm_term=%5BTWS%5D%20%26%20%5BMaster%20%2B%20Not%20Dormant%5D
Comments
0 comments
Please sign in to leave a comment.